Reduced expression of CD44 and CD155 following siRNA-KD in SNB-19 cells.

<p><b>a</b>, siRNA-KD of CD44 and CD155 was confirmed by Western blotting using both wild type (<i>wt</i>) and non-targeting siRNA treated cells as controls. GAPD-siRNA was used as a positive control to validate the knockdown effect. <b>b</b>, Expression of CD44 (<b>top panels</b>) and CD155 (<b>bottom panels</b>) in non-targeting siRNA treated cells (<b>control/left panels/L</b>) and relevant siRNA-KD (<b>right panels/R</b>) cells; scale bars: 25 µm. In control cells (<b>L</b>), CD44 is uniformly distributed with intense staining at the edges of the cells (arrows) whereas CD155 is well distributed with dense staining zones at the leading edges of the cells (arrows). CD44/CD155 staining was reduced in the siRNA-KD cells with clearly altered morphology (<b>R</b>). <b>c</b>, CD44/CD155-KD was confirmed by flow cytometry. Expression levels of CD44 and CD155 were significantly reduced in siRNA-KD SNB-19 cells as indicated by percentage of positive cells and fluorescence fold. * indicates statistical significance compared to non-targeting siRNA treated cells (control).